Bone Demineralization in Postmenopausal Women: Role of Anamnestic Risk Factors

Table 2

Bone mineral density (BMD), TSH and markers of osteoblastic and osteoclastic activities before (T0) and two years (T2) after followup in 50 postmenopausal patients did not receive any therapy (control group).

	T0	T1
BMD (T-score)	−0.27±0.02	−0.30±0.07
TSH (μIU/mL)	1.4±0.2	1.5±0.04
Serum calcium concentration (mg/dL)	9.1±0.06	9.2.8±0.01
Urinary calcium excretion (mg/24h)	144.2±2.1	146.4±2.2
Alkaline phosphatase (UI/L)	160.7±1.5	160.9±1.2
Urinary hydroxyproline excretion (mg/m^2/24 h)	13.1±0.6	13.0±0.1

^∗𝑃<0.001 versus T0.
Normal values: TSH: 0.49–4.67 μU/L; serum calcium concentration: 8.2–10.5 mg/dL; urinary calcium excretion: 50–250 mg/24 h; alkaline phosphatase: 98–279 UI/L; urinary hydroxyproline excretion (22–65 yrs): 6–22 mg/m²/24 h.